Core Viewpoint - The company has announced its third-quarter report for 2025, ensuring the accuracy and completeness of the financial information presented, and has made significant governance changes including the cancellation of the supervisory board and adjustments to the board of directors [8][11][13]. Financial Data - The third-quarter financial report is not audited, and the company has confirmed that the financial data is accurate and complete [3][5]. - The report includes major financial indicators and accounting data, although specific figures are not disclosed in the provided documents [3][4]. Governance Changes - The company has proposed to cancel the supervisory board and adjust the number of directors, which requires shareholder approval [13][16]. - The board has also approved amendments to the company's articles of association and governance rules in light of these changes [16][22]. Shareholder Meeting - A temporary shareholder meeting is scheduled for November 17, 2025, to discuss the proposed governance changes and other matters [63][64]. - The meeting will utilize both in-person and online voting methods to facilitate participation [65][66]. International Expansion - The company plans to sign a distribution and marketing agreement with Helios and Early Morning International for its product Efparepoetin alfa in Vietnam, aiming to enhance its international market presence [47][48]. - This agreement is part of the company's strategy to internationalize its products and improve brand influence [60]. Product Development - The product Efparepoetin alfa is a recombinant fusion protein aimed at treating anemia in chronic kidney disease patients and is currently under development with significant R&D investment [50][51]. - The company has invested approximately 51.24 million yuan in the development of this product as of September 30, 2025 [51].

(本文来自第一财经) 步长制药公告，控股子公司泸州步长与Helios、早安国际签署《经销、营销服务和代理协议》，泸州步 长拟授权Helios在目标区域内完成注射用Efparepoetin alfa的独家营销和经销。注射用Efparepoetin alfa （注射用依派促红素α），适用于治疗正在接受促红细胞生成素治疗的成人透析患者因慢性肾脏病 （CKD）引起的贫血，为治疗用生物制品I类新药，目前已提交上市申请。 ...

转自：证券时报 人民财讯10月29日电，步长制药(603858)10月29日公告，公司控股子公司泸州步长拟与越南公司 Helios、早安国际签署《经销、营销服务和代理协议》，泸州步长拟授权Helios作为越南区域内经销 商、早安国际作为目标区域内中间商，在目标区域内完成注射用Efparepoetin alfa的独家营销和经销。注 射用Efparepoetin alfa（注射用依派促红素α），适用于治疗正在接受促红细胞生成素治疗的成人透析患 者因慢性肾脏病（CKD）引起的贫血。步长制药同日披露2025年第三季度报告，第三季度实现归母净 利润2.41亿元，同比增长195.44%。 ...